Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment
about
Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subjectMetabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells.Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, CanadaA critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatmentAcute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study.Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Fat feeding potentiates the diabetogenic effect of dexamethasone in Wistar rats.Factors associated with response to clozapine in schizophrenia: a review.Do serum lipids predict response to clozapine treatment?Verbal memory improvement in first-episode psychosis APOE-ε4 carriers: a pleiotropic effect?Clozapine-induced Acute Hypertriglyceridemia.The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review.Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
P2860
Q28073082-F7DA0C4B-7550-48A4-83AA-4F05704BCA67Q30459096-7F0889C6-7AE6-441E-8461-0ED3AED7166AQ33498169-825D8044-5EA9-4F1A-8FA5-6FC7032454E0Q34139645-49E191F4-02C9-457B-8C05-7AF2D9655EA7Q34405264-DB56A220-F3EF-4C1E-B6B9-FC142FFA8CD1Q34506022-7B993774-71C3-4C02-B18C-436B45AE9F9AQ35675775-87A37CB1-3B49-4B37-A121-E9E988A459F7Q36113742-7804DE2C-74BF-4FA8-A6DB-59F9701358B6Q36164661-2716697F-42AA-461F-A9DE-973B9A8A6668Q36383322-EBAEB9FA-BDF4-4C6A-A60B-BE961720A167Q36702009-45DBF987-E13D-4705-8C87-C9A4E6DA142DQ37300007-A7DF445D-37E7-46CA-9841-0E39C4587B60Q41898024-8E32111B-9EF8-40B8-8AB3-60AD96CF8E94Q47102005-2C493E5A-C75F-4B64-A4D9-DB64EBCD2533Q47124581-50BAC7AA-A62B-406A-ADD8-F0670882BF22Q49481418-FCEDF928-84FC-4087-A025-6BF4A4FB692EQ52579281-9EAB7948-1E0D-4424-BA2D-7A1A33E2E731Q58791341-74CB8F4F-111F-40AB-97D4-E16FD271EDC0
P2860
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Changes in serum lipids, indep ...... long-term clozapine treatment
@ast
Changes in serum lipids, indep ...... long-term clozapine treatment
@en
type
label
Changes in serum lipids, indep ...... long-term clozapine treatment
@ast
Changes in serum lipids, indep ...... long-term clozapine treatment
@en
prefLabel
Changes in serum lipids, indep ...... long-term clozapine treatment
@ast
Changes in serum lipids, indep ...... long-term clozapine treatment
@en
P2093
P2860
P50
P1476
Changes in serum lipids, indep ...... long-term clozapine treatment
@en
P2093
Allen E Thornton
Clozapine and Risperidone Enhancement Study Group
Edith Pomarol-Clotet
Emmanuel Stip
Eric Y H Chen
G William Macewan
Kishor M Wasan
Richard Williams
P2860
P304
P577
2007-09-01T00:00:00Z